It’s time to reshape your expectations

Introducing Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a combined hormonal once-weekly birth control patch that’s purposefully designed for her.

Twirla is for use in women of reproductive potential with a BMI <30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Consider Twirla’s reduced effectiveness in women with a BMI ≥25 to <30 kg/m2 before prescribing.

Demonstrated Efficacy
Not actual size.

Purposefully inclusive trial

Efficacy and safety were evaluated in a purposefully inclusive trial that featured a diverse study population, closely representative of the demographics of women across the US.1-3

SECURE TRIAL

A lower estrogen dose than the only other patch

Twirla delivers 30 mcg of estrogen daily, the lowest exposure of estrogen in a transdermal contraceptive option.4

Transdermal Hormonal Delivery

Woven, flexible fabric

Twirla utilizes proprietary patch technology, designed with a woven, flexible fabric.


For illustrative purposes only.
Skinfusion® Technology

IMPORTANT SAFETY INFORMATION

+

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥30 kg/m2

Cigarette Smoking and Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TWIRLA, are contraindicated in women who are over 35 years of age and smoke.

Contraindicated in Women with a BMI ≥30 kg/m2

TWIRLA is contraindicated in women with a BMI ≥30 kg/m2. Compared to women with a lower BMI, women with a BMI ≥30 kg/m2 had reduced effectiveness and may have a higher risk for venous thromboembolic events (VTEs).